A Case of a Rare STRN-ALK Fusion in Esophagus Adenocarcinoma Exhibits Excellent Response to Crizotinib

Xiaofei Zhang¹, Xiao Chu², Kuaile Zhao² and Weixin Zhao^1*

¹Department of Radiation Oncology, Fudan University Shanghai Cancer Center, China

²Department of Oncology, Shanghai Medical College, China

*Corresponding Author:
Weixin Zhao
Fudan University Shanghai Cancer Center
270 Dongan Road, Xuhui, Shanghai, China
E-mail: zwx_zhxf@163.com

Received: November 12, 2020 Accepted: January 31, 2021 Published: February 20, 2021

Citation: Zhang X, Chu X, Zhao K, Zhao W. (2021) A Case of a Rare STRN-ALK Fusion in Esophagus Adenocarcinoma Exhibits Excellent Response to Crizotinib. Clin Oncol Case Rep 4:2

We present a first case of a rare STRN-ALK fusion in esophagus adenocarcinoma exhibits excellent response to crizotinib. A 36-year-old male disgnosed of esophagus adenocarcinoma. The patient recieved six cycles of new neoadjuvan-chemotherapy with the regimen of paclitaxel plus cisplatin and neoadjuvant radiotherapy with the dose of 45GY/25f. Ten months later, he received four cycles of chemotherapy with the regimen of paclitaxel plus cisplatin because that radiological examination revealed two emerging nodules in the left inner lobe of the liver and progress of nodular thickeningness of bilateral interlobar pleura and left pleura..Four months later, radiological examination revealed progression in the liver and in esophagus. Patient refused third line chemotherapy and ask for gene testing. Amplification refractory mutation system analysis revealed STRN-ALK fusion in both plasma and tissue and the patient requests to try crizotinib. To date, his liver and left pleura lesions recessed significantly. and his symptoms were greatly relieved after using crizotinib with 22-month PFS and 43-month OS.